Why aren't Drugs being Developed for the Neonatal Population by the Innovator Community?

Only available as part of a package

This module includes a brief overview of the unmet need for neonatal drug development and the necessity of more optimal engagement of neonatal nurses in neonatal clinical research.

CE Credit Information:

Participants can earn 0.25 CE credit for viewing the presentation and completing the evaluation.

The National Association of Neonatal Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Mary Short, MSN, RN

Mary Short, is a Registered Nurse, a Perinatal Clinical Nurse Specialist, and has a Master of Science in Nursing from Indiana University. Prior to her tenure at Eli Lilly and Company, Mary served as a staff nurse and Clinical Nurse Specialist at the Neonatal Intensive Care Unit (NICU) of Methodist Hospital of Indiana. Mary conducted research on positioning and neuromuscular development. Her involvement in National Association of Neonatal Nurses (NANN) included former chair of the International Relations Committee, and former president of the Central Indiana Chapter. She served on the Advances in Neonatal Care Editorial Board and was a co-series editor for Foundations in Neonatal Care. In 1994, Mary received the NANN Robyn Main Excellence in Clinical Practice Award.

Mary’s contributions to pediatric healthcare extend beyond the clinical setting. Throughout her tenure at Eli Lilly and Company, where she retired in 2020, she played a pivotal role in advancing pediatric initiatives. Notably, she spearheaded the establishment of the Pediatric Steering Committee, Pediatric Symposium, Pediatric Excellence Awards, Parent Volunteer Group, and the Pediatric Capabilities Function. Her leadership was instrumental in integrating pediatric requirements and considerations into Lilly’s quality, training, and development systems. Mary’s expertise in pediatric clinical trials significantly contributed to advancements in pediatric programs of the Biomedicines development area.

Post-retirement, Mary continues to be actively engaged in advocating for children’s unmet medical and drug development needs. She serves as a co-chair for the International Neonatal Consortium Communications Work Group. Mary provides consultation services for pediatric drug development and has interest in promoting multistakeholder engagement to improve the successful completion of pediatric research. She has authored multiple peer-reviewed journal publications.